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The results of amputation free survival (AFS) of a cohort of 887
caucasian patients is shown.
The data is based on further analyses of data presented in Jalkanen
et al. (2016) [1]. The 36-month amputation free survival of patients
divided in new crural vessel disease classiﬁcation (Crural Index), aor-
toiliac TASC II classiﬁcation, femoropopliteal TASC II classiﬁcation and
most severe segment is presented. Also, in depth demographic data is
presented for each Crural Index group Jalkanen et al., 2016 [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
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Value of the data This is the ﬁrst analyses of correlation between AFS and crural index.
 The data demonstrates the challenging nature of extensive crural disease. The more extensive the
atherosclerosis on crural vessels is, the more interventions are needed.
 Present data shows that in addition to poor survival and AFS, crural index IV is associated with
conservative treatment and inability to treat.
 It also provides estimation of survival and amputation free survival for TASC II classiﬁcation for
aortoiliac and femoropopliteal segments [2–4].1. Data
The presented data is acquired from analysis of amputation free survival and extent of
atherosclerosis in crural vessels of PAD patients. Patient cohort was analysed according to
widely used classiﬁcation (TASC II) [2–4] and a new classiﬁcation for the crural vessels [1]. The
Kaplan-Meier curves for AFS are shown in Fig. 1A and B. Table 1A–E presents the mean AFS7SEves show the cumulative amputation free survival (AFS) during 36-months follow-up. Separate
and for patients with no detectable signiﬁcant atherosclerotic lesion in crural arterial vessels. The
x IV demonstrates the poor prognosis of patients with extensive atherosclerosis in crural arteries.
ve marked at deﬁned time-point. B. Kaplan–Meier curves demonstrating amputation free survival
eased vascular segments. A more detailed presentation of data analysis is given in the methods
arked as aorto-iliac (AI), femoro-popliteal (FP) and crural (Cr). Severe crural lesions result predict a
or each curve marked at deﬁned time-point.
Table 1
The analyses of treatments in each Crural index group. Unable to treat percentage of cases not being able to treat either for the
technical reasons or patient unﬁt for demanded surgery. Conservative includes unable to treat and patients with claudication
and requiring too extensive revascularisation procedures for clinical symptom. Endovascular procedures during 36-months
follow-up to the initially worse leg. Surgical revascularisations to initially worse leg during 36-months follow-up. Treatments to
the initially worse leg during 36-month follow-up, including both endovascular and surgical procedures. Amputation free
survival (AFS) 1, 2 and 3 years.
A
Crural Index Grade 0 Grade I Grade II Grade III Grade IV
Unable to treat 3.20% 11% 4.30% 5.20% 9.60%
Conservative 7.1% 20% 16% 18% 31%
Endovascular 54% 67% 65% 62% 49%
Surgery 49% 23% 30% 39% 32%
Treatments (mean7SE) 1.370.086 1.0671.102 1.1070.047 1.3170.068 0.09870.073
AFS 1, 2, 3 years 87%, 81%, 79% 77%, 76%, 73% 79%, 74%, 74% 67%, 60%, 58% 49%, 40%, 37%
B
Most severe segment Aorto-iliac Femoro-popliteal Crural
Unable to treat 2.10% 0.10% 14%
Conservative 7% 12% 31%
Endovascular 65% 61% 56%
Surgery 43% 44% 21%
Treatments (mean7SE) 1.2870.072 1.3670.052 0.8970.045
AFS 1, 2, 3 years 86%, 79%, 78% 80%, 75%, 74% 51%, 44%, 41%
Table 2
Mean estimated amputation free survival during 36-months follow-up, SE and 95% CI presented in the table for A)
Aorto-iliac (AI), B) Femoro-popliteal (FP), C) Crural (Cr) grades I–IV, D) Localization of signiﬁcant atherosclerotic
lesion, E) The most severe atherosclerotic segment. Log-rank test shown on the left row of the table. Number of
patients at risk for each group n.
(n) Mean
months7SE
95% CI; LowerUpper
Bound
A AI I 92 32.171.06 30.134.2
AI II 57 31.271.58 28.134.3
AIII 34 27.672.27 23.132.0
P¼0.010 AIIV 65 28.571.59 25.431.6
B FP I 82 28.671.60 25.5729.4
FP II 140 29.271.09 27.0731.3
FP III 114 28.271.22 25.8730.6
p¼0.335 FP IV 329 27.370.758 25.8728.8
C Cr I 70 30.471.50 27.533.4
Cr III 235 30.770.772 29.232.2
Cr III 289 26.770.835 25.128.4
Po0.001 Cr IV 166 21.071.17 18.723.3
D AI 25 36.570.47 35.637.4
FP 61 32.771.30 30.235.3
Cr 144 24.371.24 21.926.8
AIþFP 36 32.671.48 29.735.5
AIþCr 48 33.071.45 30.235.8
FPþCr 428 27.070.685 25.728.4
Po0.001 AIþFPþCr 138 27.771.14 25.429.9
E AI 140 32.570.849 30.834.1
FP 417 31.270.565 30.032.3
Po0.001 Cr 325 21.870.844 20.223.5
Overall 27.970.460 27.028.8
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Table 3
Mean estimated survival during 36-months follow-up, SE and 95% CI presented in the table for A) Aorto-iliac (AI), B) Femoro-
popliteal (FP), C) Crural (Cr) grades I–IV, D) Localization of signiﬁcant atherosclerotic lesion, E) The most severe atherosclerotic
segment. Log-rank test shown on the left row of the table. Number of patients at risk for each group n.
(n) Mean Months7SE 95% CI; Lower-Upper
Bound
A AI I (92) 32.471.01 30.534.4
AI II (57) 31.571.52 28.534.5
AI III (34) 27.672.31 23.032.1
P¼0.128 AI IV (66) 31.071.36 28.433.7
B FP I (82) 29.771.52 26.732.7
FP II (140) 29.971.05 27.831.9
FP III (114) 28.971.19 26.531.2
P¼0.247 FP IV (330) 28.870.700 27.430.2
C Cr I (70) 31.471.38 28.734.1
Cr II (235) 31.470.710 30.032.8
Cr III (289) 28.470.789 26.829.9
P¼0.000 Cr IV (167) 23.271.14 20.925.4
D AI (25) 36.270.48 35.637.5
FP (61) 32.871.26 30.335.3
Cr (144) 26.671.15 24.428.9
AIþFP (36) 33.371.43 30.536.1
AIþCr (48) 33.371.40 30.536.0
FPþCr (429) 28.470.648 27.129.6
P¼0.030 AIþFPþCr (139) 28.971.06 26.831.0
E AI (141) 33.770.713 32.335.1
FP (416) 31.970.530 30.832.9
P¼0.000 Cr (325) 23.870.813 22.225.3
Overall 29.270.430 28.330.0
a Estimation is limited to the largest survival time 37 months
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Table 2A–E shows patient survival during 36-month follow-up divided correspondingly to
Table 1 AFS Table 3.2. Experimental design, materials and methods
The data is based on 887 consecutive patients admitted to the Department of Vascular Surgery at
the Turku University Hospital (Turku, Finland) either for diagnostic DSA or for endovascular treatment
of PAD from January 1st 2009 to July 30th 2011. All patients were included regardless of earlier PAD
history. Deaths and amputations within the patient cohort were registered for the ﬁrst 36-months,
which was the cut-off point for follow-up.
2.1. DSA analysis
The index classiﬁcation was as described in TASC II for aorto-iliac and femoro-popliteal seg-
ments. Aorto-iliac and femoro-popliteal segments TASC II classiﬁcation A–D, (coded as 1–4) were
for the statistical analyses. For the crural region, all three vessels were ﬁrst analysed separately
and a Crural Index was formed accordingly (see for further description [1]). In order to assess
J.M. Jalkanen et al. / Data in Brief 8 (2016) 242–246246different vascular segments against each other, each patient was assigned into a speciﬁc group of
disease localisation: 1) aorto-iliac, 2) femoro-popliteal or 3) crural, based on which 0–IV rating
gave the highest number.
2.2. Statistical analyses
All statistical analyses were performed using the IBM SPSS version 22 statistics program. Con-
tinuous variables were expressed as mean7standard error (SE). Survival analyses were assessed by
Kaplan–Meier curves and Log-rank statistics.Acknowledgements
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